Alzheimer’s disease seminar

DRA symposium

Alzheimer's disease is a devastating disease, which affects millions of people worldwide. But despite extensive research, numerous questions are still left unanswered. What causes the disease and which pathological hallmarks are relevant for (pharmacological) interventions?

This seminar combines national and international recognized experts from the clinic, academia, and spinout providing overview and novel insights to the disease, current treatment options, and potential future therapeutic interventions.

Sign up via ALZHEIMER’S DISEASE seminar - Danmarks Farmaceutiske Selskab (farmaceutisk-selskab.dk)

Programme

16:15-16:30 Coffee & snacks
16:30-16:35

Welcome by the Danish Pharmaceutical Society
Mie Kristensen & Steen Ingwersen
Section of Biopharmacy, Danish Pharmaceutical Society

16:35-17:15

Alzheimer’s disease – the disease and current standard care

Kristian Steen Frederiksen, Associate Professor, Senior Hospital Physician
Danish Dementia Research Centre, Rigshospitalet

17:15-17:45

Brain energy accounting in Alzheimer’s disease

Blanca Aldana, Associate Professor
Department of Drug Design and Pharmacology, University of Copenhagen

17:45-18:05 Refreshments
18:05-18:35

The story of Lecanemab: From bench to bedside

Dag Sehlin, Associate Professor

Department of Public Health and Caring Sciences, Uppsala University

18:35-19:05

Light as novel treatment option for Alzheimer’s disease patients

Jes Broeng & Marcus Carstensen, Co-founders OPTOCEUTICS

19:05-19:15

Wrap up

Mie Kristensen & Steen Ingwersen

Section of Biopharmacy, Danish Pharmaceutical Society


The symposium is organized on behalf of the graduate programme in pharmaceutical sciences, Drug Research Academy, by Associate Professor Mie Kristensen, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen in collaboration with the Section for Biopharmaceuticals, Danish Pharmaceutical Society.

The symposium is free of charge and open for attendance by all interested parties.